1 Use of antihypertensive drugs and breast cancer risk: a two-

2 sample Mendelian randomization study

3 Guoqiao Zheng ^{1*}, Subhayan Chattopadhyay ², Jan Sundquist ^{1, 3, 4}, Kristina Sundquist ^{1, 3, 4},

- 4 Jianguang Ji¹
- 5

6 Affiliations of authors:

7 1 Center for Primary Health Care Research, Lund University/Region Skåne, Malmö, Sweden

8 2 Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund,
9 Sweden

10 3 Department of Family Medicine and Community Health, Department of Population Health

11 Science and Policy, Icahn School of Medicine at Mount Sinai, New York, USA

12 4 Center for Community-based Healthcare Research and Education (CoHRE), Department of

13 Functional Pathology, School of Medicine, Shimane University, Japan

14

15 *Correspondence: Dr. Guoqiao Zheng, Center for Primary Health Care Research, Lund

- 16 University/Region Skåne, Jan Waldenströms gata 35, 205 02 Malmö, Sweden.
- 17 Phone: +46 (40) 39 13 79
- 18 Email: guoqiao.zheng@med.lu.se
- 19 ORCID: <u>https://orcid.org/0000-0003-4337-9017</u>
- 20
- 21

22 Short title: MR association between antihypertensive drugs and BC risk

23 Word count: abstract: 231, main text: 3696

24 Key words: antihypertensive medication, cancer risk, causal association, drug repurposing,

25 adverse drug effect

26

27

28 ABSTRACT

29 Background

30 Observational studies regarding the correlation between the use of antihypertensive 31 medication and the risk of breast cancer (BC) reported inconsistent findings. We performed a 32 two-sample Mendelian randomization using instrumental variables to proxy changes in gene 33 expressions of antihypertensive medication targets to interrogate this.

34 Methods

We assessed the association between single-nucleotide polymorphisms (SNPs) and drug targetable gene expression with expression quantitative trait loci in blood. Further, we investigated association between the SNPs and BC risk with genome-wide association study summary statistics. We then confirmed the hits from Mendelian randomization with tissuespecific analyses along with additional sensitivity assessments (horizontal pleiotropy, colocalization, multiple tissue enrichment etc.).

41 **Results**

The overall BC risk was decreased 16% with one standard deviation (SD) increase of 42 SLC12A2 gene expression in blood (odds ratio, 0.86, 95% confidential interval, 0.78-0.94). 43 This signal was further confirmed in estrogen receptor positive (ER+) BC (0.85, 0.78-0.94). 44 45 In addition, one SD increase in expression of PDE1B in blood was associated with 7% increased risk of ER+ BC (1.07, 1.03-1.11). We detected no evidence of horizontal pleiotropy 46 for these associations and the probability of the causal variants being shared between the gene 47 expression and BC risk was 81.5%, 40.5% and 66.8%, respectively. We failed to observe any 48 49 significant association between other targeted genes and BC risk.

50 **Conclusions**

51 Use of antihypertensive medications that target *SLC12A2* and *PDE1B* is associated with 52 increased and decreased BC risk, respectively.

53 Funding

- 54 This work was supported by the Swedish Research Council [2018-02400 to K.S., 2020-01175
- to J.S., 2021-01187 to J.J.], Cancerfonden [2017 CAN2017/340 to J.J.], Crafoordska
- 56 Stiftelsen [to J.J.], MAS Cancer [to J.J.], ALF funding from Region Skåne [to J.J. and K.S.].
- 57 The funding body was not involved in the design of the study and collection, analysis, and
- 58 interpretation of data and in writing the manuscript.

59 INTRODUCTION

60 Nearly one in three adults is estimated to have hypertension globally (1). Antihypertensive 61 drugs are the most commonly prescribed medication in Sweden with over 2.1 million patients taking anti-hypertensive drugs in 2020 (2). These drugs are usually prescribed to hypertensive 62 63 patients as a long-term management (3). Given the large disease burden and high consumption of the antihypertensive medication, there are concerns surrounding their 64 65 carcinogenic potential as well as interests regarding their possible anti-cancer effect since the 66 targets of these drugs are widely distributed in normal tissue and may be involved in tumor 67 development. For example, renin-angiotensin system, the target for angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs), contains components 68 69 that promote or inhibit cellular proliferation (4). Many observational studies with cohort or case-control design have evaluated the possible link between antihypertensive medication and 70 71 risk of breast cancer (BC) (5-7), the most common type of cancer and the leading cause of 72 cancer death among women worldwide (8). However, the results are conflicting, as these 73 studies suffer from various biases, including unmeasured confounding, immortal time bias, 74 indication and surveillance bias, which might result in inconsistent conclusions. Due to such 75 shortcomings of the observational studies, previous results could not draw causative 76 conclusions. In addition, there are ethical constraints for conducting randomized clinical trials 77 (RCTs). Therefore, we opted for an alternative design to investigate the causal effect of antihypertensive medications on BC risk. 78

79 Mendelian randomization (MR) mimics a natural experiment by using genetic variants as a proxy (instrumental variable) for the modifiable exposure (9). The principle is that 80 81 randomization occurs naturally at conception when genetic variants are allocated at random to 82 individuals from their parents. Consequently, the inherited genetic variants are independent of 83 potential confounding environmental exposures. MR can be regarded as analogous to an RCT 84 that uses genetic variation as the method of randomization ultimately providing causal insights. In addition, the risk estimated from MR reflects a lifetime risk, which is longer than 85 86 the follow-up in RCT. MR has successfully identified unintended drug effects including 87 adverse drug effects and drug repurposing (10, 11). As for the association between 88 antihypertensive medication and cancer risk, Yarmolinsky et. al. reported long-term ACE inhibition to be associated with an increased risk of colorectal cancer by using a MR analysis 89 90 (12). However, the ARB, a common antihypertensive medication (13), was not included in the 91 analysis. Additionally, the instrumental variable for each class of drug was selected based on

92 only one targeted gene. However, antihypertensive drugs may act on multiple targets involved 93 in different pathways, thus capturing all the possible targets with corresponding instrumental 94 variables for each drug are needed. Finally, the expression quantitative trait loci (eQTL) for 95 the targeted genes from *Yarmolinsky et. al.* was derived only from the whole blood, whereas 96 the targeted genes may be differentially expressed in a tissue-specific manner (14).

97 Here we aimed to investigate the effect of antihypertensive medication use on BC risk using a
98 two-sample MR design with a consideration of all the commonly prescribed medication for
99 hypertension, and exploring the eQTL from both the whole blood and several other tissues.
100 This study will add evidence to the current knowledge derived from observational studies and
101 try to draw causal conclusions regarding the potential association between antihypertensive
102 medication use on BC risk.

103

104 MATERIAL AND METHODS

105 This study is based on a couple of publicly available databases, which are summarized in the Supplementary Table 1. We used the summary statistics of these publically available 106 107 databases, and we did not access individual information. We constructed a two-sample MR design where the summary statistics for the association measures are independently evaluated 108 109 for the exposure (i.e., genetic component and the gene expression) and the outcome (i.e., genetic component and BC). We began by assessing the association between a single-110 nucleotide polymorphism (SNP) and drug targeted gene expression derived from publicly 111 112 derived eQTL data in whole blood. In this, three basic assumptions must have held (9): 1) The 113 genetic variants are associated with the risk factor of interest (relevance assumption); 2) There 114 are no unmeasured confounders of the associations between genetic variants and outcome 115 (independence assumption); 3) The genetic variants affect the outcome only through their 116 effect on the risk factor of interest (exclusion restriction). To evaluate and establish the significant MR associations, we further performed tissue-specific analyses to confirm the hits 117 along with additional sensitivity analyses, including assessment of horizontal pleiotropy, 118 119 colocalization analysis, and multiple tissue enrichment evaluations. The design flow chart is 120 demonstrated in Figure 1.

121 1. Identification of drug target genes

The commonly prescribed antihypertensive medications, including ACEis, ARBs, betablockers (BB), calcium channel blockers (CCB), diuretics and antihypertensives, were considered in the analysis (13). We identified the genes targeted by different classes of anti-

125 hypertensive medication through DrugBank (15).

126 2. Discovery of genetic instruments for targeted gene expression

To identify common SNPs (minor allele frequency >1%) associated with the targeted gene expression of antihypertensive drug in blood, we extracted publicly available expression quantitative trait loci (eQTL) data from eQTLGen (<u>https://www.eqtlgen.org/</u>). The consortium incorporates 37 datasets, with a total of 31,684 individuals and reports on 16,987 genes expressed in whole blood. The eQTL SNPs for this analysis were from *cis*-regulated regions (2 Mb). We used F statistic to assess the strength of the instrumental SNPs.

133 3. Validation of genetic instrument with systolic blood pressure GWAS

134 Given that we are trying to identify instruments for blood pressure-lowering medication, we 135 performed two-sample MR analysis with gene expression in blood (using the eQTL data) as exposure and systolic blood pressure (SBP) as the outcome to ensure we have valid 136 137 instruments for the medication of interest. The summary statistics for SBP was a GWAS of SBP in 757 601 individuals of European ancestry drawn from UK Biobank (UKB) and the 138 International Consortium of Blood Pressure Genome Wide Association Studies (ICBP) (16). 139 The summary-based MR (SMR) method (version 1.02) was used to perform the two-sample 140 MR analysis (17). It tests a top SNP against the eQTL summary. For SNPs that passed the 141 142 significance threshold for the SMR test (i.e., P < 0.05), additionally we performed the HEIDI (heterogeneity in dependent instruments) test to distinguish pleiotropy from linkage with P-143 value threshold of 0.01, in which up to the top 20 SNPs by default were used for 144 145 heterogeneity test with LD pruning (0.05 - 0.9) (17).

146

147 4. Accumulation of genetic summary statistics for breast cancer risk

We obtained publicly available GWAS summary statistics for BC risk from the Breast Cancer
Association Consortium (BCAC). The analysis for the overall BC risk included 118,474 cases
and 96,201 controls of European ancestry participating in 82 studies (18). For analyses of BC
molecular subtypes, 7,325 participants were included for luminal A-like cases, 1,779 for
luminal B/HER2-negative-like cases, 1,682 for luminal B-like cases, 718 for HER2-enriched-

153 like, 2,006 for triple-negative cases and 20,815 for controls (18). We also obtained the GWAS

summary statistics for estrogen receptor-positive (ER+) and -negative (ER-) BC from BCAC,

which contained 69,501 ER+ BC cases, 21,468 ER- BC cases and 105,974 controls (19).

156 5. MR analysis between targeted gene expression in blood and breast cancer risk

We performed MR analysis to estimate the association between target gene expression change (using whole blood eQTL) and BC risk (using GWAS). Bonferroni correction was used to identify significant associations due to multiple testing. For the association that reached corrected significant level, we generated SMR locus plot using the method presented on SMR webpage (<u>https://yanglab.westlake.edu.cn/software/smr/#Overview</u>).

162 **6.** Sensitivity analyses

163 **6.1 Colocalization analysis** This analysis is to assess if two independent association signals at the same locus, typically generated by two GWAS studies, are consistent with a shared 164 165 causal variant. In the context of our study, we examined if the drug targeted gene expression 166 and occurrence of BC in statistically significant MR associations shared a common causal 167 variant by applying a Bayesian localization approach (20). As a convention, the posterior 168 probability larger than 0.80 is considered supportive for a common causal variant. The R package 'coloc' (v3.1, https://cran.r-project.org/web/packages/coloc/) was used to perform 169 170 the test.

171 **6.2** Assessment of horizontal pleiotropy A genetic variant can be associated with more than one gene expression, which is known as horizontal pleiotropy. Horizontal pleiotropy is a 172 violation of the instrumental variable assumption (exclusion restriction) that the genetic 173 174 instrument is associated with the outcome only via changes in gene expression of the drug target. We tested for horizontal pleiotropy by extracting available associations with all other 175 176 nearby genes (within a 2Mb window) for each genetic instrument. For the nearby genes showing significant association with the genetic instrument, we performed SMR analysis to 177 178 test if the expression of these genes was associated with BC risk. For those genes with significant SMR associations, colocalization analysis was performed to estimate the 179 180 probability that two association signals share the same causal variant.

6.3 Multiple tissue sensitivity We then evaluated the impact of the actionable targets in
several different tissues along with whole blood and breast epithelium. Gene set enrichment
analysis was performed with the assorted drug target genes to quantify all biological pathways

prone to be affected by the drugs. RNA seq data on different tissues (except prostate and testis) were utilized for this purpose and analyzed with R package 'TissueEnrich' (21). The enrichment analysis queries expression modulation with fold changes across different human tissue types. A significant departure was defined at an adjusted fold change in expression of value 2 and the fold change was also tested for statistical significance. For tissues that showed significant fold changes, further MR association between tissue specific eQTL and BC risk were retrieved from summary statistics reported by Barbeira et. al. (22).

6.4 Differential gene expression in Expression Atlas To verify the associations that have
shown causal variant and signaled no horizontal pleiotropy, we retrieved transcriptomic data
of the significant genes for tumor tissue (or other tissue from BC patients) and normal tissue
(or other tissue from healthy controls) on Expression Atlas (https://www.ebi.ac.uk/gxa/home).
Differential gene expressions between tissues were evaluated as fold change using normal
tissue (or other tissue from healthy controls) as reference.

197 6.5 MR analysis to estimate the association of SBP with breast cancer

198 To determine whether the association between drug targeted gene expression and BC risk is 199 likely to be mediated via changes in blood pressure or whether the association may be driven 200 independently, we estimated the effect size for the association between genetically estimated 201 SBP and BC using the generalized summary data-based MR (GSMR) method (23). The 202 GSMR (implemented in Genome-wide Complex Trait Analysis, version 1.91.7) is an 203 extension of SMR that uses multiple genetic variants associated with the risk factor to test for 204 potential causality. The above-mentioned GWAS summary statistics on SBP (exposure) and 205 overall BC risk (outcome) in European individuals were used for the analysis. As usual, a HEIDI P < 0.01 was used to detect outlying variants. In addition, we performed two-sample 206 207 MR analysis using "Two-Sample MR" R package to check the consistency of the signals from 208 the two different methods.

209

210 **RESULTS**

211 Genetic Instrument Selection and Validation

We identified a total of 164 blood pressure modulatory drugs from the WHO Collaborating Centre for Drug Statistics Methodology (<u>https://www.whocc.no/</u>). In DrugBank database, 124 of them were identified to target a total of 154 genes. There were expectedly several overlaps

between drug classes and associated targets (Figure 2, details in Supplementary Table 2).

For example, *SLC12A2* can be targeted by quinethazone, bumetanide and torasemide, and at the same time, torasemide can also target on gene *SLC12A1*. Among the 154 chosen targeted

218 genes, 72 genes were identified to have strong association with the eQTL SNPs in eQTLGen

219 (F statistic > 10, $P_{eOTL} < 1e-8$), among which, 32 were found to be causally associated with

SBP with statistical significance (P < 0.05). A total of 23 associations were confirmed by the

- HEIDI outlier test (p HEIDI > 0.01), which were further considered in the MR analysis with
- BC as the outcome (Supplementary Table 3). It should be noted that the number of SNPs in
- HEIDI test for gene P4HA1 was less than five (n=3).

224 MR analysis for association of targeted gene in blood and overall and subtypes BC risk

In the analysis of MR association between the targeted genes in blood and overall BC risk, we 225 226 identified significant associations for five genes including P4HA1, SLC12A2, KCNJ11, CA12 227 and PDE1B, but only the association for SLC12A2 was significant with Bonferroni correction $(0.05/23=2.2 \times 10^{-3})$ (Table 1). One standard deviation increase in the expression of *SLC12A2* 228 was associated with 14% decrease in BC risk (odds ratio, OR, 0.86, 95% confidence interval, 229 230 95%CI, 0.78-0.94). This association was supported by the HEIDI outlier test. The SMR locus plot for this association is shown in Figure 3. With the same analysis for ER+ and ER- BC 231 232 (Table 2), a nominal significance was observed in the association between ER+ BC risk and 233 expressions of P4HA1, SLC12A2, KCNJ11 and PDE1B, among which SLC12A2 and PDE1B were still significant after Bonferroni correction $(0.05/(23 \times 2)=1.1 \times 10^{-3})$. One SD increase in 234 the SLC12A2 expression was associated with 15% decrease in the risk of ER+ BC (0.85, 0.78-235 0.94), while one SD increase in *PDE1B* expression was associated with 7% increased risk 236 (1.07, 1.03-1.11). For ER- BC, only SLC12A2 showed a nominal significance but it was not 237 238 significant while considering multiple testing. For the molecular subtype of BC (see **Table 2**), 239 we found P4HA1, SLC12A2, KCNJ11 and CA12 were associated with luminal A-like BC with 240 nominal significance, P4HA1, SLC12A2, ATP1A1, NR3C1, CA12, CACNA1D and GPR35 for 241 luminal B-like BC, SLC12A2 and SCNN1D for luminal B/HER2-negative-like BC, ACE for 242 HER2-enriched-like BC and AOC1 for triple-negative BC. However, none of them was significant after Bonferroni correction $(0.05/(23 \times 5)=4.3 \times 10^{-4})$. 243

244 Sensitivity analyses

245 We conducted several sensitivity analyses to evaluate the discovered significant associations

between targetable gene expression and BC risk. The associations for the top SNP pertaining

to *SLC12A2* and *PDE1B* with nearby genes within the 2MB window are shown in

248 Supplementary Table 4. In the test for horizontal pleiotropy, gene CTC-228N24.3 within the

249 2MB window of *SLC12A2* was also found significant association with BC risk

250 (Supplementary Table 5). The P-value of the SMR association for CTC-228N24.3 was

similar to that of *SLC12A2*. However, the posterior probability for a common variant between

252 CTC-228N24.3 and overall BC risk was 77%, less than that for SLC12A2 (81.5%). The

253 posterior probability for a common causal variant between *SLC12A2* expression and risk of

ER+ BC was 40.5% and for *PDE1B* was 66.8%. None of the corresponding nearby genes

showed a higher probability than *SLC12A2* and *PDE1B*.

256 In the tissue enrichment analysis, 16 different tissues were found enriched with targeted genes

257 (Supplementary Figure 1). We further measured the statistical significance of the

associations which largely overlapped with the observation of fold change. Interestingly,

smooth muscular, cervical, gallbladder, endometrium, adrenal gland, small seven intestine,

260 placenta, skeletal muscle and kidney were found significant. The MR associations for the

available tissue in GTEx are shown in Supplementary Table 6. Only expression of PDE1B

in mammary tissue was negatively associated with BC risk (OR, 0.88, 95%CI, 0.82-0.95), but

it was not significant after considering Bonferroni correction $(0.05/(23\times7)=3.1\times10^{-4})$.

264 We uncovered five data resources in Expression Atlas (see Supplementary Table 7), which

contained gene expression of *SLC12A2* for invasive BC tissue (or other tissue from BC

266 patients) and normal tissue (or other tissue from healthy controls). The samples were either

from blood or breast tissue. Four datasets indicated that SLC12A2 expression in BC tissue (or

blood from BC patients) was lower than that in normal tissue (or blood from healthy

controls). Only one showed the opposite association and the type of the BC was invasive

270 ductal carcinoma.

271 MR association between systolic blood pressure and overall BC risk

272 We performed MR with GSMR and TwoSampleMR to test if SBP was associated with

overall BC risk using SBP GWAS data as exposure and BC GWAS as the outcome. The

results indicated no evidence of the causal association between genetically estimated SBP and

275 BC risk (Supplementary Table 8).

276

277 DISCUSSIONS

278 With this two-sample Mendelian randomization study, we observed that the overall BC risk

- was decreased 16% along with one SD increase of *SLC12A2* gene expression. *SLC12A2*
- encodes Na(+)-K(+)-2Cl(-) cotransporter isoform 1 (NKCC1), which can be targeted by loop
- 281 diuretics including torasemide, bumetanide and quinethazone. Thus, long-term use of these
- drugs may potentially increase overall BC risk. The significant association with the
- expression of *SLC12A2* was further observed with ER+ BC. In addition, a SD increase in
- 284 expression of *PDE1B*, which can be targeted by three CCBs: nicardipine, felodipine and
- bepridil, was associated with 7% increased risk of ER+ BC. We did not observe any
- significant association between other targeted genes and BC risk.
- 287 A recent meta-analysis evaluated the association between antihypertensive medication use
- and BC according to 57 conventional observational studies and also reported that use of
- 289 diuretics was associated with increased BC risk (24). However, this study also found
- 290 increased BC risk among users of BBs, or CCBs (24), which is inconsistent with our result.
- 291 Another meta-analysis based on RCTs concluded no consistent evidence that antihypertensive
- medication use had any effect on cancer risk (25). Our results are in agreement with the
- findings from Yarmolinsky et. al. who investigated antihypertensive drug use and risk of
- common cancers by evaluating SNPs in ACE, ADRB1, and SLC12A3 in GWAS of SBP to
- 295 proxy genetic inhibition of the angiotensin-converting enzyme (ACE), β -1 adrenergic receptor
- 296 (ADRB1), and sodium-chloride symporter (NCC) (12). None of the inhibited targets were
- associated with the risk of BC (12). Unlike this MR study which only considered one targeted
- 298 gene for each type of antihypertensive drug, we included all the targets and validated the
- 299 instruments through systolic blood pressure GWAS.
- 300 The mechanisms that links *SLC12A2* gene expression and BC risk are unclear. The GSMR
- analysis for the association between SBP and BC risk indicates that the effect of the drugs on
- 302 BC risk was not through blood pressure, which is consistent with the finding that there is no
- evidence of genetic correlation between blood pressure and BC risk (26). The *SLC12A2*-
- 304 coded protein, NKCC1 has been reported to be involved in mammary gland development and
- 305 regulate breast morphogenesis (27). So far, very few studies have investigated the association
- of BC risk and use of loop diuretics, although among which furosemide targets also NKCC2,
- a homogeneous protein of NKCC1. A meta-analysis based on four studies found that the
- relative risk of BC among users of loop diuretics was 0.91(0.77-1.06) compared to nonusers.
- 309 Elsewhere an in vitro study reported expression of *SLC12A2* in BC cell to be downregulated
- by the treatment with estrogen (28), which is a well-known risk factor for BC. This finding is

in accordance with our current study where SLC12A2 expression was found protective against 311 312 BC risk and this association was only significant for ER+ BC. It should be noted that the case 313 number of ER-BC GWAS was much less than ER+ BC GWAS which might detail the loss of 314 signal. Four out of five datasets from Expression Atlas also indicated lower expression of SLC12A2 in BC tissue (or tissue from BC patients) than the normal tissue (or tissue from 315 controls). On contrary, several in vitro studies reported that inhibition of NKCC1 could 316 reduce cell proliferation, invasion and/or migration in glioblastoma, glioma, esophageal 317 318 squamous cell carcinoma, hepatocellular carcinoma and gastric cancer cells which may 319 indicate a global underlying tumor-inhibiting mechanism (29-35). Sun et. al. also found that 320 increased expression of NKCC1 was associated with poor prognosis in lung adenocarcinoma and EGFR-mutated adenocarcinoma (36). More studies are required to investigate the role of 321

322 NKCC1 in BC etiology.

323 *PDE1B* was the only other gene that showed the association with ER+BC risk. The function

of protein PDE1B includes dopaminergic signaling, immune cell activation, and cell survival.

325 It is one of the family members of phosphodiesterases (PDEs) that hydrolyze cyclic adenosine

326 monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP); the latter two

327 participate in many physiological processes such as visual transduction, cell proliferation and

differentiation, and cell-cycle regulation (37). Some tumor cells overexpress PDEs and as a

consequence, the level of cAMP/cGMP in tumor cells is lower than the normal cells (38).

330 PDEs have become the potential therapeutic target to increase intracellular cAMP/cGMP and

thus inhibit tumor growth (39, 40). PDE1B can be targeted by miR-5701 to inhibit

proliferation and promote apoptosis of clear cell renal cell carcinoma cells (41). Wittliff et.al.

used gene expression of *PDE1B* and several other genes to predict the overall survival of

breast carcinoma (42). However, in the tissue-specific MR, the results for the mammary gland

contradict the current evidence, which needs further investigation.

336 We need to emphasize the strengths and weaknesses of the causal nature of this study design. Use of GWAS summary statistics with two sample MR increases statistical power. The 337 338 application of genetic variants to proxy the use of antihypertensive medication reduces the 339 chance of confounding, misclassification and immortal time bias that are common caveats in a 340 conventional observational study (43). The different targeted-gene expression was obtained 341 since fetus, which provides the opportunity to observe the effect of antihypertensive 342 medication on BC risk in a long term. Compared to RCT, our study is more efficient as cancer 343 is a late-onset disorder and needs long-term follow-up time. Using the plethora of publicly

344 available summary statistics from GWAS, MR was performed without recruiting new patients 345 or designing additional studies like RCT. We conducted multiple sensitivity analyses such as 346 colocalization analysis and pleiotropy test to evaluate the viability of the assumptions of the instrument variables and to reduce chance findings. As for limitations, the exploration of the 347 molecular subtype of BC was underpowered due to small sample size. Larger GWAS data 348 from the consortium are needed to remedy such issue. The effect of differed gene expression 349 on BC risk due to polymorphism may not be the same as that due to the use of 350 351 antihypertensive medication, as the former exposure is from early-life time and the latter 352 mostly from adulthood. Therefore, our results provide a strong signal to select existing drugs 353 (NKCC1-targeted antihypertensive medication) to be validated with RCT. Our results may 354 only be applied to European population and research among other population is needed. Additionally, our results suggest future studies could focus on the association between 355 356 expression level of NKCC1 protein and BC risk, which may provide evidence on risk reduction. 357

358

359 CONCLUSIONS

By using two-sample MR, we found BC risk was negatively associated with expression of

361 *SLC12A2*, and ER+ BC risk was positively associated with expression of *PDE1B*. Therefore,

the use of antihypertensive medication targeting *SLC12A2* and *PDE1B* will be associated

363 respectively increased and decreased risk. The observed effect on the BC risk was

364 independent of systolic blood pressure.

365

366 DECLARATIONS

- 367 Availability of data and materials: The data that support the findings of this study are
- 368 publicly available. The sources have been summarized in **Supplementary Table 1**. Any

369 request regarding the data from this study should go to Z.G..

370 **Ethical approval and consent to participate:** All the data for this study were publicly

- available summary statistics. Therefore, ethical approval and consent to participate were not
- 372 required.

373 **Consent for publication:** Not applicable.

- 374 **Competing interests:** The authors declare no competing interests.
- 375 Author contributions: Design: GZ, JJ. Work platform access: JS, KS. Statistical analysis and
- interpretation: GZ, SC, JJ, JS, KS. Manuscript writing: GZ and all other authors. Approval of
- 377 the final text: All authors.

378

379 REFERENCE:

Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nature Reviews
 Nephrology. 2020:1-15.

382 2. Statistik om läkemedel 2020. 2021.

3833.Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, et al. Breast384cancer. Nature Reviews Disease Primers. 2019;5(1):66.

 Wegman-Ostrosky T, Soto-Reyes E, Vidal-Millán S, Sánchez-Corona J. The reninangiotensin system meets the hallmarks of cancer. Journal of the Renin-Angiotensin-Aldosterone System. 2015;16(2):227-33.

Li CI, Daling JR, Tang M-TC, Haugen KL, Porter PL, Malone KE. Use of antihypertensive
 medications and breast cancer risk among women aged 55 to 74 years. JAMA internal medicine.
 2013;173(17):1629-37.

Gómez-Acebo I, Dierssen-Sotos T, Palazuelos C, Pérez-Gómez B, Lope V, Tusquets I, et
 al. The use of antihypertensive medication and the risk of breast cancer in a case-control study in a
 Spanish population: the MCC-Spain study. PLoS One. 2016;11(8):e0159672.

3947.Raebel MA, Zeng C, Cheetham TC, Smith DH, Feigelson HS, Carroll NM, et al. Risk of395Breast Cancer With Long-Term Use of Calcium Channel Blockers or Angiotensin-Converting Enzyme396Inhibitors Among Older Women. American Journal of Epidemiology. 2017;185(4):264-73.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics
 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
 CA: a cancer journal for clinicians. 2018;68(6):394-424.

400 9. Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies: a
 401 guide, glossary, and checklist for clinicians. BMJ. 2018;362:k601.

40210.Yin P, Anttila V, Siewert KM, Palotie A, Davey Smith G, Voight BF. Serum calcium and403risk of migraine: a Mendelian randomization study. Hum Mol Genet. 2017;26(4):820-8.

404 11. Swerdlow DI, Preiss D, Kuchenbaecker KB, Holmes MV, Engmann JEL, Shah T, et al.
405 HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic
406 analysis and randomised trials. Lancet. 2015;385(9965):351-61.

Yarmolinsky J, Diez-Obrero V, Richardson TG, Pigeyre M, Sjaarda J, Pare G, et al.
Genetically-proxied therapeutic inhibition of antihypertensive drug targets and risk of common
cancers. medRxiv. 2021.

410 13. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018

411 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the

412 management of arterial hypertension of the European Society of Cardiology (ESC) and the European

413 Society of Hypertension (ESH). European heart journal. 2018;39(33):3021-104.

414 14. Ferreira MA, Gamazon ER, Al-Ejeh F, Aittomäki K, Andrulis IL, Anton-Culver H, et al. 415 Genome-wide association and transcriptome studies identify target genes and risk loci for breast 416 cancer. Nature communications. 2019;10(1):1-18. 417 Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, et al. DrugBank 5.0: a major 15. 418 update to the DrugBank database for 2018. Nucleic acids research. 2018;46(D1):D1074-D82. Evangelou E, Warren HR, Mosen-Ansorena D, Mifsud B, Pazoki R, Gao H, et al. Genetic 419 16. 420 analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. Nat 421 Genet. 2018;50(10):1412-25. 422 17. Zhu Z, Zhang F, Hu H, Bakshi A, Robinson MR, Powell JE, et al. Integration of summary 423 data from GWAS and eQTL studies predicts complex trait gene targets. Nature genetics. 424 2016;48(5):481-7. 425 Zhang H, Ahearn TU, Lecarpentier J, Barnes D, Beesley J, Qi G, et al. Genome-wide 18. 426 association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-427 specific analyses. Nature Genetics. 2020;52(6):572-81. 428 19. Milne RL, Kuchenbaecker KB, Michailidou K, Beesley J, Kar S, Lindström S, et al. 429 Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nat 430 Genet. 2017;49(12):1767-78. 431 20. Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, Wallace C, et al. 432 Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. 433 PLoS Genet. 2014;10(5):e1004383. 434 21. Jain A, Tuteja G. TissueEnrich: Tissue-specific gene enrichment analysis. 435 Bioinformatics. 2018;35(11):1966-7. 436 Barbeira AN, Bonazzola R, Gamazon ER, Liang Y, Park Y, Kim-Hellmuth S, et al. 22. 437 Exploiting the GTEx resources to decipher the mechanisms at GWAS loci. Genome Biology. 438 2021;22(1):49. 439 23. Zhu Z, Zheng Z, Zhang F, Wu Y, Trzaskowski M, Maier R, et al. Causal associations 440 between risk factors and common diseases inferred from GWAS summary data. Nature 441 communications. 2018;9(1):1-12. 442 24. Xie Y, Wang M, Xu P, Deng Y, Zheng Y, Yang S, et al. Association Between 443 Antihypertensive Medication Use and Breast Cancer: A Systematic Review and Meta-Analysis. 444 Frontiers in pharmacology. 2021;12:1169. 445 Copland E, Canoy D, Nazarzadeh M, Bidel Z, Ramakrishnan R, Woodward M, et al. 25. 446 Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis. The 447 Lancet Oncology. 2021;22(4):558-70. 448 26. Jiang X, Finucane HK, Schumacher FR, Schmit SL, Tyrer JP, Han Y, et al. Shared 449 heritability and functional enrichment across six solid cancers. Nature Communications. 450 2019;10(1):431. 451 27. Shillingford JM, Miyoshi K, Flagella M, Shull GE, Hennighausen L. Mouse mammary 452 epithelial cells express the Na-K-Cl cotransporter, NKCC1: characterization, localization, and 453 involvement in ductal development and morphogenesis. Molecular endocrinology. 2002;16(6):1309-454 21. 455 28. Wright PK, May FE, Darby S, Saif R, Lennard TW, Westley BR. Estrogen regulates vesicle 456 trafficking gene expression in EFF-3, EFM-19 and MCF-7 breast cancer cells. International journal of 457 clinical and experimental pathology. 2009;2(5):463. 458 29. Luo L, Guan X, Begum G, Ding D, Gayden J, Hasan MN, et al. Blockade of cell volume 459 regulatory protein NKCC1 increases TMZ-induced glioma apoptosis and reduces astrogliosis. 460 Molecular cancer therapeutics. 2020;19(7):1550-61. 461 30. Zhou Y, Sun W, Chen N, Xu C, Wang X, Dong K, et al. Discovery of NKCC1 as a potential 462 therapeutic target to inhibit hepatocellular carcinoma cell growth and metastasis. Oncotarget.

463 2017;8(39):66328.

464 31. Algharabil J, Kintner DB, Wang Q, Begum G, Clark PA, Yang S-S, et al. Inhibition of Na+-465 K+-2Cl-cotransporter isoform 1 accelerates temozolomidemediated apoptosis in glioblastoma cancer 466 cells. Cellular Physiology and Biochemistry. 2012;30(1):33-48. 467 Haas BR, Sontheimer H. Inhibition of the sodium-potassium-chloride cotransporter 32. 468 isoform-1 reduces glioma invasion. Cancer research. 2010;70(13):5597-606. Wang J-f, Zhao K, Chen Y-y, Qiu Y, Zhu J-h, Li B-p, et al. NKCC1 promotes proliferation, 469 33. 470 invasion and migration in human gastric cancer cells via activation of the MAPK-JNK/EMT signaling 471 pathway. Journal of Cancer. 2021:12(1):253. 472 34. Schiapparelli P, Guerrero-Cazares H, Magaña-Maldonado R, Hamilla SM, Ganaha S, 473 Fernandes EGL, et al. NKCC1 regulates migration ability of glioblastoma cells by modulation of actin 474 dynamics and interacting with cofilin. EBioMedicine. 2017;21:94-103. 475 Shiozaki A, Nako Y, Ichikawa D, Konishi H, Komatsu S, Kubota T, et al. Role of the 35. 476 Na+/K+/2Cl-cotransporter NKCC1 in cell cycle progression in human esophageal squamous cell 477 carcinoma. World Journal of Gastroenterology: WJG. 2014;20(22):6844. 478 36. Sun P-L, Jin Y, Park SY, Kim H, Park E, Jheon S, et al. Expression of Na+–K+-2Cl– 479 cotransporter isoform 1 (NKCC1) predicts poor prognosis in lung adenocarcinoma and EGFR-mutated 480 adenocarcinoma patients. QJM: An International Journal of Medicine. 2016;109(4):237-44. 481 37. Peng T, Gong J, Jin Y, Zhou Y, Tong R, Wei X, et al. Inhibitors of phosphodiesterase as 482 cancer therapeutics. European journal of medicinal chemistry. 2018;150:742-56. 483 38. Levy I, Horvath A, Azevedo M, de Alexandre RB, Stratakis CA. Phosphodiesterase 484 function and endocrine cells: links to human disease and roles in tumor development and treatment. 485 Current opinion in pharmacology. 2011;11(6):689-97. 486 Huang W, Sundquist J, Sundquist K, Ji J. Phosphodiesterase-5 inhibitors use and risk for 39 487 mortality and metastases among male patients with colorectal cancer. Nat Commun. 488 2020;11(1):3191. 489 40. Huang W, Sundquist J, Sundquist K, Ji J. Use of Phosphodiesterase 5 Inhibitors Is 490 Associated With Lower Risk of Colorectal Cancer in Men With Benign Colorectal Neoplasms. 491 Gastroenterology. 2019;157(3):672-81 e4. 492 41. Zhao C, Mo L, Lei T, Yan Y, Han S, Miao J, et al. miR-5701 promoted apoptosis of clear 493 cell renal cell carcinoma cells by targeting phosphodiesterase-1B. Anti-Cancer Drugs. 2021;32(8):855-494 63. 495 42. Wittliff JL, Sereff SB, Daniels MW. Expression of genes for methylxanthine pathway-496 associated enzymes accompanied by sex steroid receptor status impacts breast carcinoma 497 progression. Hormones and Cancer. 2017;8(5):298-313. 498 43. Walker VM, Davey Smith G, Davies NM, Martin RM. Mendelian randomization: a novel 499 approach for the prediction of adverse drug events and drug repurposing opportunities. International 500 journal of epidemiology. 2017;46(6):2078-89. 501 502 503 504 505 506 507

508

509

510	
511	
512	
513	FIGURE LEGENDS
514	Figure 1. The flowchart of the study.
515	Mendelian randomization, SMR, summary-based MR, eQTL, expression quantitative trait
516	loci, SNP, single-nucleotide polymorphism, HEIDI, heterogeneity in dependent instruments,
517	BC, breast cancer.
518	Figure 2. A network of established links between hypertension drugs considered and the
519	corresponding target genes.
520	Each color represents a different class of drugs (annotated in the histogram) and the circle size
521	represents the number of drugs belonging to a class. Abbreviations: CCB, calcium channel
522	blockers, BB, beta-blockers, AH, antihypertensives, ACEi, angiotensin-converting enzyme
523	inhibitors, ARBs, angiotensin receptor blockers.
524	Figure 3. MR association between <i>SLC12A2</i> gene expression in blood and breast cancer risk
525	(a) Top, P values from the GWAS for breast cancer (grey dots) and P values from SMR tests
526	(diamonds). Bottom, P values eQTL data for SLC12A2 and CTC-228N24.3. Shown in a are all
527	the SNPs available in the GWAS and eQTL data. (b) Effect sizes of the SNPs (used for the
528	HEIDI test) from the GWAS against those from the eQTL data. The orange dashed lines
529	represent the estimate of effect size of the MR association at the top cis-eQTL (rather than the
530	regression line). Error bars are the standard errors of SNP effects.
531	
532	

Table 1 MR association between drug target gene expression in blood and overall risk of breast cance	r

Gene	Pro beC hr	Probe_bp	topSNP	topS	topSNP_b p	Effe ct_a llele	Oth er_a llele	Freq_ Effect_ allele	eQTL association			BC asso	ociation		MR ass	ociation	HEIDI Test		
				NP_c hr					beta	se	р	beta	se	р	beta	se	р	р	nsn p
SLC12A2	5	127472419	rs17764730	5	127357526	Т	С	0.21	-0.186	0.009	3.2E-86	0.028	0.007	7.57E-05	-0.150	0.039	1.05E-04	1.56E-01	20
P4HA1	10	74811853	rs6480668	10	74849326	G	А	0.24	0.183	0.016	3.35E-32	-0.032	0.012	7.83E-03	-0.176	0.068	9.47E-03	4.98E-01	8
CA12	15	63643968	rs12909041	15	63743677	А	С	0.36	0.039	0.010	1.14E-04	-0.026	0.008	6.88E-04	-0.670	0.263	1.08E-02	5.35E-01	5
PDE1B	12	54958078	rs10747699	12	54955324	Т	С	0.39	0.406	0.009	0.00E+00	0.017	0.007	1.31E-02	0.041	0.017	1.32E-02	3.63E-01	3
KCNJ11	11	17409142	rs2074310	11	17421886	Т	С	0.26	0.157	0.012	4.37E-38	-0.015	0.006	1.99E-02	-0.092	0.040	2.20E-02	8.06E-02	20
NR3C1	5	142736286	rs4912908	5	142791133	G	А	0.17	0.073	0.010	1.07E-13	0.016	0.008	4.67E-02	0.221	0.115	5.47E-02	2.81E-02	15
ATP1A1	1	116934086	rs6704439	1	116867616	А	С	0.30	0.041	0.009	4.39E-06	0.015	0.008	5.47E-02	0.363	0.205	7.64E-02	8.28E-01	20
KCNJ2	17	68170501	rs9890133	17	68169005	G	А	0.15	-0.256	0.012	8.02E-94	-0.015	0.010	1.12E-01	0.060	0.038	1.13E-01	9.60E-01	20
SLC12A1	15	48540068	rs964611	15	48597514	А	С	0.15	1.664	0.009	0.00E+00	-0.012	0.009	1.78E-01	-0.007	0.005	1.78E-01	9.86E-01	20
CACNA2D2	3	50470954	rs62260815	3	50474624	А	G	0.05	-0.142	0.013	8.98E-29	-0.013	0.010	2.03E-01	0.089	0.070	2.06E-01	3.88E-01	20
AHR	7	17362011	rs17643734	7	17162882	G	А	0.03	0.478	0.016	3.7E-184	0.015	0.013	2.70E-01	0.030	0.028	2.71E-01	9.83E-01	20
ACE	17	61576813	rs4277405	17	61548918	С	Т	0.35	0.075	0.009	1.59E-17	0.006	0.006	3.18E-01	0.083	0.084	3.21E-01	9.97E-01	20
AQP1	7	30929070	rs2075574	7	30950744	Т	С	0.37	0.113	0.013	3.77E-19	-0.008	0.009	3.50E-01	-0.073	0.078	3.53E-01	7.67E-01	5
SLC9A1	1	27459389	rs6683016	1	27493194	Т	С	0.28	-0.096	0.008	9E-31	-0.004	0.006	5.37E-01	0.041	0.066	5.38E-01	7.61E-02	20
AOC1	7	150540153	rs7806458	7	150476888	G	А	0.28	0.669	0.008	0.00E+00	-0.003	0.006	6.20E-01	-0.005	0.009	6.20E-01	7.63E-01	20
CACNA1H	16	1237506	rs117177120	16	1238875	G	Т	0.02	0.372	0.024	4.41E-54	0.004	0.016	7.82E-01	0.012	0.042	7.82E-01	4.21E-01	20
SLC16A1	1	113477052	rs1049434	1	113456546	А	Т	0.32	0.125	0.008	9.29E-54	0.002	0.006	8.02E-01	0.013	0.050	8.02E-01	4.06E-01	20
GPR35	2	241557762	rs2975788	2	241571858	G	А	0.43	0.293	0.009	6.2E-259	0.002	0.007	8.10E-01	0.005	0.022	8.10E-01	5.79E-01	20
CACNA1D	3	53687586	rs9830632	3	53735766	G	А	0.29	-0.085	0.009	2E-22	-0.001	0.007	9.19E-01	0.008	0.080	9.19E-01	3.50E-01	20
ADRB2	5	148207176	rs2082395	5	148200600	А	G	0.35	0.126	0.008	6.31E-56	-0.001	0.006	9.37E-01	-0.004	0.050	9.37E-01	7.18E-01	4
CA4	17	58237778	rs34820870	17	58244021	G	Т	0.16	-0.462	0.021	6.1E-110	0.001	0.016	9.50E-01	-0.002	0.036	9.50E-01	9.89E-01	20
JUN	1	59248125	rs2716140	1	59472397	С	А	0.39	-0.228	0.008	3.5E-177	0.000	0.007	9.57E-01	0.002	0.030	9.57E-01	9.06E-01	20
SCNN1D	1	1221612	rs6662635	1	1220425	G	А	0.08	-0.475	0.044	4.76E-27	-0.001	0.031	9.80E-01	0.002	0.064	9.80E-01	9.46E-01	20

534 Beta of MR association represents the log odds per one standard deviation increase in gene expression. A significant HEIDI p-value (<0.01) indicates that any association

between gene expression and outcome may be due to linkage where there are two distinct causal variants in linkage disequilibrium.

17

536 537	MR, Mendelian randomization, SNP, single nuclear polymorphism, eQTL, expression quantitative trait loci, se, standard error, BC, breast cancer, HEIDI, heterogeneity in dependent instruments, nsnp, number of SNPs for HEIDI test.
538	
539	
540	
541	
542	
543	
544	
545	
546	
547	
548	
549	
550	
551	
552	
553	
554	
555	
556	

CND aim 1 alaar nalumarnhism aOTI . etitative tweit last as standard a DC broost a UEIDI hat 526 MD M 11 . • .• •, •

BC type		Gene	Pr ob	Probe_bp	topSNP	topS NP_ chr	topSNP_b p	ect h _al r lel a	Ot	Fre ~ E	eQTL	association		BC association			MR asso	ociation	HEIDI Test		
			eC hr						he r_ all ele	q_E ffect _all ele	beta	se	р	beta	se	р	beta	se	р	р	ns np
Estrogen	Positive	P4HA1	10	74811853	rs6480668	10	74849326	G	А	0.24	0.183	0.016	3.35E-32	-0.045	0.015	2.49E-03	-0.247	0.084	3.30E-03	3.72E-01	8
receptor status		SLC12A2	5	127472419	rs17764730	5	127357526	Т	С	0.21	- 0.186	0.009	3.20E-86	0.029	0.009	6.96E-04	-0.158	0.048	8.67E-04	1.23E-01	20
		KCNJ11	11	17409142	rs2074310	11	17421886	Т	С	0.26	0.157	0.012	4.37E-38	-0.016	0.008	4.20E-02	-0.099	0.050	4.53E-02	4.33E-01	20
		PDE1B	12	54958078	rs1874308	12	54954356	А	Т	0.39	0.429	0.009	0.00E+00	0.030	0.008	3.38E-04	0.070	0.019	3.28E-04	2.37E-01	14
	Negative	SLC12A2	5	127472419	rs17764730	5	127357526	Т	С	0.21	- 0.186	0.009	3.20E-86	0.037	0.013	5.13E-03	-0.200	0.072	5.75E-03	7.17E-01	20
molecular characteri	Luminal A-like	P4HA1	10	74811853	rs6480668	10	74849326	G	А	0.24	0.183	0.016	3.35E-32	-0.044	0.016	6.35E-03	-0.238	0.090	7.84E-03	9.37E-01	8
stics	А-шке	PDE1B	12	54958078	rs1874308	12	54954356	А	Т	0.39	0.429	0.009	0.00E+00	0.023	0.009	9.75E-03	0.053	0.020	9.86E-03	5.67E-01	14
		CA12	15	63643968	rs12909041	15	63743677	А	С	0.36	0.039	0.010	1.14E-04	-0.024	0.010	1.51E-02	-0.632	0.307	3.97E-02	5.06E-01	6
		SLC12A2	5	127472419	rs17764730	5	127357526	Т	С	0.21	- 0.186	0.009	3.20E-86	0.019	0.009	4.35E-02	-0.101	0.050	4.46E-02	9.57E-01	20
	Luminal B- like	P4HA1	10	74811853	rs6480668	10	74849326	G	А	0.24	0.183	0.016	3.35E-32	-0.093	0.037	1.11E-02	-0.506	0.204	1.31E-02	9.98E-01	8
		GPR35	2	241557762	rs2975788	2	241571858	G	А	0.43	0.293	0.009	6.23E- 259	-0.044	0.019	2.02E-02	-0.151	0.065	2.05E-02	1.21E-02	20
		SLC12A2	5	127472419	rs17764730	5	127357526	Т	С	0.21	- 0.186	0.009	3.20E-86	0.044	0.020	3.24E-02	-0.236	0.111	3.34E-02	1.73E-02	20
		CACNA1 D	3	53687586	rs9830632	3	53735766	G	А	0.29	- 0.085	0.009	2.00E-22	0.042	0.020	3.17E-02	-0.499	0.238	3.59E-02	6.17E-01	20
		CA12	15	63643968	rs12909041	15	63743677	А	С	0.36	0.039	0.010	1.14E-04	-0.056	0.023	1.29E-02	-1.457	0.697	3.66E-02	8.70E-01	6
		ATP1A1	1	116934086	rs6704439	1	116867616	А	С	0.30	0.041	0.009	4.39E-06	0.050	0.022	2.10E-02	1.216	0.590	3.92E-02	9.63E-01	20
		NR3C1	5	142736286	rs4912908	5	142791133	G	А	0.17	0.073	0.010	1.07E-13	0.047	0.023	3.76E-02	0.649	0.324	4.53E-02	3.31E-01	14
	luminal B/HER2-	SLC12A2	5	127472419	rs17764730	5	127357526	Т	С	0.21	- 0.186	0.009	3.20E-86	0.054	0.017	1.82E-03	-0.292	0.095	2.08E-03	6.53E-01	20
	negative- like	SCNN1D	1	1221612	rs6662635	1	1220425	G	А	0.08	- 0.475	0.044	4.76E-27	-0.206	0.080	1.03E-02	0.434	0.174	1.26E-02	3.35E-01	20
	HER2- enriched	KCNJ11	11	17409142	rs2074310	11	17421886	Т	С	0.26	0.157	0.012	4.37E-38	-0.041	0.027	1.28E-01	-0.258	0.171	1.31E-01	6.21E-01	20
	childhea	ACE	17	61576813	rs4277405	17	61548918	С	Т	0.35	0.075	0.009	1.59E-17	0.069	0.026	7.99E-03	0.918	0.363	1.13E-02	1.93E-01	20
	Triple- negative	AOC1	7	150540153	rs7806458	7	150476888	G	А	0.28	0.669	0.008	0.00E+00	-0.031	0.016	4.97E-02	-0.046	0.024	4.97E-02	9.62E-01	20

557	Table 2 MR association between drug target gene expression in blood and ris	sk of breast cancer subtype according to ER status and molecular characteristics

- Beta of MR association represents the log odds per one standard deviation increase in gene expression. A significant HEIDI p-value (<0.01) indicates that any association
 between gene expression and outcome may be due to linkage where there are two distinct causal variants in linkage disequilibrium.
- 561 MR, Mendelian randomization, SNP, single nuclear polymorphism, eQTL, expression quantitative trait loci, se, standard error, BC, breast cancer, HEIDI, heterogeneity in
- be dependent instruments, nsnp, number of SNPs for HEIDI test.




Figure 1. The flowchart of the study. Mendelian randomization, SMR, summarybased MR, eQTL, expression quantitative trait loci, SNP, single-nucleotide polymorphism, HEIDI, heterogeneity in dependent instruments, BC, breast cancer.




Figure 2. A network of established links between hypertension drugs considered and the corresponding target genes. Each color represents a different class of drugs (annotated in the histogram) and the circle size represents the number of drugs belonging to a class. Abbreviations: CCB, calcium channel blockers, BB, beta-blockers, AH, antihypertensives, ACEi, angiotensin-converting enzyme inhibitors, ARBs, angiotensin receptor blockers.




Figure 3. MR association between SLC12A2 gene expression in blood and breast cancer risk

(a) Top, P values from the GWAS for breast cancer (grey dots) and P values from SMR tests (diamonds). Bottom, P values eQTL data for SLC12A2 and CTC-228N24.3. Shown in a are all the SNPs available in the GWAS and eQTL data. (b) Effect sizes of the SNPs (used for the HEIDI test) from the GWAS against those from the eQTL data. The orange dashed lines represent the estimate of effect size of the MR association at the top cis-eQTL (rather than the regression line). Error bars are the standard errors of SNP effects.